With FDA panel nod, ThromboGenics closer to first potential drug

ThromboGenics came closer to having its first approved drug on the U.S. market, gaining an FDA advisory committee recommendation for its lead drug candidate, ocriplasmin, for combatting vision-impairing vitreomacular adhesion. The Belgian biotech and Novartis ($NVS), which controls ex-U.S. rights to the drug, have an addressable market of 500,000 patients with the biologic in the U.S. and Europe, according to ThromboGenics. The FDA action date for potential U.S. approval of the treatment is October 17. Article